March 12, 2018
  • Lumentum (LITE) and Oclaro (OCLR): Lumentum Holdings Inc. and Oclaro, Inc. announced that they signed a definitive agreement pursuant to which Lumentum will acquire all of the outstanding common stock of Oclaro for $5.60 per share in cash and 0.0636 shares of Lumentum common stock in a deal valued at approximately $1.8 billion. Lumentum stated that it expects the acquisition to result in more than $60 million of annual run-rate synergies within 12 to 24 months of the closing and to be immediately accretive to its non-GAAP earnings per share. The companies expect the acquisition to close during the second half of 2018.
  • Clorox (CLX): The Clorox Company announced that it entered into a definitive agreement to acquire Nutranext, a privately-held manufacturer of dietary supplements, for $700 million. Clorox stated that it expects the acquisition to be dilutive to its fiscal 2018 and 2019 earnings per share but to be accretive to its earnings per share during the company’s fiscal year ending June 30, 2020.
  • Biogen (BIIB): Biogen Inc. announced that it entered into an agreement to acquire Pfizer Inc.’s receptor potentiator for cognitive impairment associated with schizophrenia for an upfront payment of $75 million and up to $515 million in development and commercialization milestone payments, as well as tiered royalties in the low to mid-teen percentages.